AUSTIN, Texas – April 6, 2016 – Lumos Pharma, a biotechnology company focused on developing therapeutics for orphan diseases, announced the successful completion of a $34 million Series B financing.  Lumos will use the proceeds for clinical trials and commercialization of its lead compound, LUM-001, for the treatment of Creatine Transporter Deficiency (CTD). Funding will…

AUSTIN, Texas – February 16, 2016 – In recognition of Rare Disease Day, members of the Lumos team will attending the local Rare Disease Day event, Cup of Hope, a chili cook-off, sponsored by U.R. Our Hope, in Kyle, Texas on Saturday, February 20th.   Also in attendance and hosting a booth, will be Whitnie Strauss, Vice…

AUSTIN, Texas – February 4th, 2014 – Lumos Pharma, an early stage biopharmaceutical development company, announced today that it has raised $14 million in Series A financing. The round was co-led by Santé Ventures and New Enterprise Associates (NEA). Lumos Pharma will use the financing to support the preclinical and clinical development of its lead…

AUSTIN, Texas – May 4th, 2015 – Lumos Pharma, Inc. (Austin, Texas) announced today that it has received an award of up to $5.5 million from the Translation Fund of the Wellcome Trust. CEO of Lumos Pharma, Richard Hawkins, stated “We are very pleased Wellcome Trust has selected Lumos for an award and we are privileged…

AUSTIN, Texas – July 12th, 2014 Researchers will begin drug development projects for rare and neglected diseases that include potential treatments for a musculoskeletal disorder, a cognitive dysfunction disorder, a virus that affects the central nervous system of newborns, a parasitic worm infection, a form of muscular dystrophy and a rare lung disease. The six…